People often get immunotherapy as a treatment for cancer. These immunotherapy treatments can be effective, but they may cause your immune system to have an unnatural response. Your body, as a result ...

Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial. This is an ASCO Meeting ...

CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases. The review, encompassing 19 studies, reveals a high incidence of CRS in patients with ...

Immune reconstitution inflammatory syndrome (IRIS) is a complex and often severe complication that can develop in HIV‐infected individuals undergoing antiretroviral therapy (ART), particularly when ...

While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to ...

For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving. It’s important for patients receiving bispecific antibodies for lymphoma or ...

With the newly approved indication for CRS, Avtozma IV now aligns with all approved indications for Actemra IV. CRS is a life-threatening condition in which an overactive immune response leads to the ...

The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...

Discover effective strategies for monitoring and managing CRS toxicity and ICANS, enhancing patient care and reducing burdens in treatment. Bispecific antibodies have transformed the treatment ...

Rates infection related cancer have increased among solid organ transplant recipients, CDC reports a five-fold rise in Kaposi sarcoma virus transmission.